Literature DB >> 10819504

Role of hormones in mammary cancer initiation and progression.

I H Russo1, J Russo.   

Abstract

Breast cancer, the most frequent spontaneous malignancy diagnosed in women in the Western world, is a classical model of hormone dependent malignancy. There is substantial evidence that breast cancer risk is associated with prolonged exposure to female hormones, since early onset of menarche, late menopause, hormone replacement therapy and postmenopausal obesity are associated with greater cancer incidence. Among these hormonal influences a leading role is attributed to estrogens, either of ovarian or extra-ovarian origin, as supported by the observations that breast cancer does not develop in the absence of ovaries, ovariectomy causes regression of established malignancies, and in experimental animal models estrogens can induce mammary cancer. Estrogens induce in rodents a low incidence of mammary tumors after a long latency period, and only in the presence of an intact pituitary axis, with induction of pituitary hyperplasia or adenomas and hyperprolactinemia. Chemicals, radiation, viruses and genomic alterations have all been demonstrated to have a greater tumorigenic potential in rodents. Chemical carcinogens are used to generate the most widely studied rat models; in these models hormones act as promoters or inhibitors of the neoplastic process. The incidence and type of tumors elicited, however, are strongly influenced by host factors. The tumorigenic response is maximal when the carcinogen is administered to young and virgin intact animals in which the mammary gland is undifferentiated and highly proliferating. The atrophic mammary gland of hormonally-deprived ovariectomized or hypophysectomized animals does not respond to the carcinogenic stimulus. Administration of carcinogen to pregnant, parous or hormonally treated virgin rats, on the other hand, fails to elicit a tumorigenic response, a phenomenon attributed to the higher degree of differentiation of the mammary gland induced by the hormonal stimulation of pregnancy. In women a majority of breast cancers that are initially hormone dependent are manifested during the postmenopausal period. Estradiol plays a crucial role in their development and evolution. However, it is still unclear whether estrogens are carcinogenic to the human breast. The apparent carcinogenicity of estrogens is attributed to receptor-mediated stimulation of cellular proliferation. Increased proliferation could result in turn in accumulation of genetic damage and stimulation of the synthesis of growth factors that act on the mammary epithelial cells via an autocrine or paracrine loop. Alternatively estrogens may induce cell proliferation through negative feedback by removing the effect of one or several inhibitory factors present in the serum. Multidisciplinary studies are required for the elucidation of the mechanisms responsible for the initiation of breast cancer. Understanding of such mechanisms is indispensable for developing a rational basis for its prevention and control.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10819504     DOI: 10.1023/a:1018770218022

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  54 in total

Review 1.  Estrogen responsiveness and control of normal human breast proliferation.

Authors:  E Anderson; R B Clarke; A Howell
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

Review 2.  Corpus luteum function and dysfunction.

Authors:  R L Stouffer
Journal:  Clin Obstet Gynecol       Date:  1990-09       Impact factor: 2.190

3.  Prolactin receptor gene expression in rat mammary gland and liver during pregnancy and lactation.

Authors:  G A Jahn; M Edery; L Belair; P A Kelly; J Djiane
Journal:  Endocrinology       Date:  1991-06       Impact factor: 4.736

Review 4.  The "epidemic" of breast cancer in the U.S.--determining the factors.

Authors:  S E King; D Schottenfeld
Journal:  Oncology (Williston Park)       Date:  1996-04       Impact factor: 2.990

5.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

6.  Progression of rat mammary development with age and its relationship to carcinogenesis by a chemical carcinogen.

Authors:  D K Sinha; J E Pazik; T L Dao
Journal:  Int J Cancer       Date:  1983-03-15       Impact factor: 7.396

7.  Influence of lobular development on breast epithelial-cell proliferation and steroid-hormone receptor content.

Authors:  G Calaf; M Alvarado; G Bonney; K Amfoh; J Russo
Journal:  Int J Oncol       Date:  1995-12       Impact factor: 5.650

8.  Effects of sequential and combined endocrine therapies on the growth of 7,12-dimethylbenz [alpha] anthracene-induced rat mammary carcinoma.

Authors:  Y Iino; T Ogawa; M Yoshida; H Ishikawa; M Izuo; H Takikawa
Journal:  Jpn J Clin Oncol       Date:  1990-09       Impact factor: 3.019

9.  Chemoprevention of N-nitroso-N-methylurea-induced mammary cancers by pretreatment with 17 beta-estradiol and progesterone.

Authors:  C J Grubbs; D R Farnell; D L Hill; K C McDonough
Journal:  J Natl Cancer Inst       Date:  1985-04       Impact factor: 13.506

Review 10.  Differentiation of the mammary gland and susceptibility to carcinogenesis.

Authors:  J Russo; L K Tay; I H Russo
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

View more
  90 in total

1.  Are the TDLU of the human the same as the LA of mice?

Authors:  R D Cardiff
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

Review 2.  Regulation of mammary gland growth and morphogenesis by the mammary fat pad: a species comparison.

Authors:  R C Hovey; T B McFadden; R M Akers
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-01       Impact factor: 2.673

Review 3.  Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones.

Authors:  R K Hansen; M J Bissell
Journal:  Endocr Relat Cancer       Date:  2000-06       Impact factor: 5.678

4.  Cdc25B functions as a novel coactivator for the steroid receptors.

Authors:  Z Q Ma; Z Liu; E S Ngan; S Y Tsai
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

Review 5.  Establishing a framework for the functional mammary gland: from endocrinology to morphology.

Authors:  Russell C Hovey; Josephine F Trott; Barbara K Vonderhaar
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-01       Impact factor: 2.673

6.  Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.

Authors:  Philipp Y Maximov; Cynthia B Myers; Ramona F Curpan; Joan S Lewis-Wambi; V Craig Jordan
Journal:  J Med Chem       Date:  2010-04-22       Impact factor: 7.446

Review 7.  Clinical opinion: the biologic and pharmacologic principles for age-adjusted long-term estrogen therapy.

Authors:  Morris Notelovitz
Journal:  MedGenMed       Date:  2006-03-28

Review 8.  Postmenopausal hormone replacement therapy: effects on normal mammary gland in humans and in a mouse postmenopausal model.

Authors:  Sandra Z Haslam; Janet R Osuch; A M Raafat; L J Hofseth
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-01       Impact factor: 2.673

9.  p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis.

Authors:  L Sivaraman; O M Conneely; D Medina; B W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

10.  Identification of CYP2C9*2 allele in HepG2 cell line.

Authors:  Jiezhong Chen; Kenneth Raymond
Journal:  Int J Gastrointest Cancer       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.